Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial
Kelly E. Dooley, Radojkam Savic, Akshay Gupte, Mark A. Marzinke, Nan Zhang, Vinodh Edward, Lisa Wolf, Modulakgotla Sebe, Morongwe Likoti, Mark J Fyvie, Innocent Shibambo, Trevor Beattie, Richard E. Chaisson, Gavin Churchyard
Topics & Concepts
RifapentineMedicineDolutegravirEfavirenzIsoniazidRegimenTuberculosisAdverse effectPharmacokineticsInternal medicineLatent tuberculosisPediatricsPharmacologyHuman immunodeficiency virus (HIV)Viral loadVirologyAntiretroviral therapyMycobacterium tuberculosisPathologyHIV/AIDS drug development and treatmentPneumocystis jirovecii pneumonia detection and treatmentHIV/AIDS Research and Interventions